Morinaga Milk’s Probiotic Bifidobacterium breve B-3 Receives Approval of Individual Recognized Registration in South Korea
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic strain Bifidobacterium breve B-3 has received the approval of Individual Recognized Registration in South Korea for its clinically demonstrated efficacy in body fat reduction.
- Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic strain Bifidobacterium breve B-3 has received the approval of Individual Recognized Registration in South Korea for its clinically demonstrated efficacy in body fat reduction.
- (Graphic: Business Wire)
On March 7, 2023, the probiotic strain B. breve B-3 received the approval of Individual Recognized Registration (No. - Bifidobacterium breve B-3 is a unique Human-Residential Bifidobacteria (HRB) probiotic strain developed by focusing on the relationship between gut microbiota and metabolic syndrome.
- The approval of the probiotic strain B. breve B-3 signifies Morinaga Milk's commitment to developing human-residential bifidobacteria (HRB) probiotic strains backed by solid scientific and clinical research.